AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for Melissa Jordan�
-0.94 (-1.62%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 56.59 - 57.87
52 week 17.14 - 59.55
Open 57.58
Vol / Avg. 409,882.00/858,496.00
Mkt cap 1.75B
P/E 15.33
Div/yield     -
EPS 3.73
Shares 29.58M
Beta 0.21
Inst. own 106%
May 21, 2015
AMAG Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 4, 2015
Q1 2015 AMAG Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 15, 2015
AMAG Pharmaceuticals Inc at Needham Healthcare Conference
Mar 2, 2015
AMAG Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 24, 2015
AMAG Pharmaceuticals Inc at RBC Healthcare Conference
Feb 11, 2015
AMAG Pharmaceuticals Inc at Leerink Global Healthcare Conference
Feb 9, 2015
Q4 2014 AMAG Pharmaceuticals Inc Earnings Call - Webcast
Feb 9, 2015
Q4 2014 AMAG Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 268.54% 109.19%
Operating margin -6.34% -3.08%
EBITD margin - 10.66%
Return on average assets 62.34% 16.42%
Return on average equity 174.63% 42.96%
Employees 257 -
CDP Score - -


1100 Winter St
WALTHAM, MA 02451-1427
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company markets Feraheme (ferumoxytol) and MuGard Mucoadhesive Oral Wound Rinse. Feraheme Injection for Intravenous (IV) is indicated for the treatment of iron deficiency anemia in adult patients with CKD. The Company offers Feraheme to both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds (mouth sores and injuries). Lumara Health, Inc. (Lumara Health), a division of AMAG Pharmaceuticals, is dedicated to advancing women�s health. Lumara Health is the exclusive marketer of Makena (hydroxyprogesterone caproate injection), a FDA-approved product indicated to reduce the risk of pre-term birth in women who are pregnant with one baby and who have delivered one pre-term baby spontaneously in the past.

Officers and directors

Gino Santini Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Frank E. Thomas President, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
William K. Heiden Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Scott A. Holmes Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer
Age: 39
Bio & Compensation  - Reuters
Scott B. Townsend Esq. Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Steven Caffe M.D. Senior Vice President, Chief Development and Regulatory Officer
Age: 54
Bio & Compensation  - Reuters
Melissa Bradford Klug Senior Vice President - Business Development and Strategy
Bio & Compensation  - Reuters
Robert Blood Esq. Chief Compliance Officer, Vice President - Legal Affairs
Bio & Compensation  - Reuters
Linda Lennox Vice President of Investor Relations, & Corporate Communications
Bio & Compensation  - Reuters